5.62 USD
+1.35 (+31.62%)
6.18 USD
+0.56 (+9.96%)
Taking everything into account, APDN scores 3 out of 10 in our fundamental rating. APDN was compared to 57 industry peers in the Life Sciences Tools & Services industry. While APDN seems to be doing ok healthwise, there are quite some concerns on its profitability. APDN is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- APDN had negative earnings in the past year.
- APDN had a negative operating cash flow in the past year.
- APDN had negative earnings in each of the past 5 years.
- In the past 5 years APDN always reported negative operating cash flow.
1.2 Ratios
- APDN's Return On Assets of -679.56% is on the low side compared to the rest of the industry. APDN is outperformed by 98.25% of its industry peers.
- The Return On Equity of APDN (-929.59%) is worse than 94.74% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -679.56% | ||
| ROE | -929.59% | ||
| ROIC | N/A |
ROA(3y)-55.66%
ROA(5y)-76.19%
ROE(3y)-114.94%
ROE(5y)-140.25%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Gross Margin of APDN (39.57%) is comparable to the rest of the industry.
- APDN's Gross Margin has declined in the last couple of years.
- The Profit Margin and Operating Margin are not available for APDN so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 39.57% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18.42%
GM growth 5Y-18.75%
2. Health
2.1 Basic Checks
- APDN does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for APDN has been increased compared to 1 year ago.
- APDN has more shares outstanding than it did 5 years ago.
- There is no outstanding debt for APDN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- APDN has an Altman-Z score of -54.74. This is a bad value and indicates that APDN is not financially healthy and even has some risk of bankruptcy.
- APDN has a worse Altman-Z score (-54.74) than 94.74% of its industry peers.
- There is no outstanding debt for APDN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -54.74 |
ROIC/WACCN/A
WACC10.45%
2.3 Liquidity
- A Current Ratio of 2.76 indicates that APDN has no problem at all paying its short term obligations.
- APDN's Current ratio of 2.76 is in line compared to the rest of the industry. APDN outperforms 50.88% of its industry peers.
- APDN has a Quick Ratio of 2.60. This indicates that APDN is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Quick ratio, with a value of 2.60, APDN is in line with its industry, outperforming 57.89% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.76 | ||
| Quick Ratio | 2.6 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 89.59% over the past year.
- The Revenue has decreased by -2.96% in the past year.
- The Revenue has been decreasing by -8.63% on average over the past years.
EPS 1Y (TTM)89.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-109.65%
Revenue 1Y (TTM)-2.96%
Revenue growth 3Y-27.56%
Revenue growth 5Y-8.63%
Sales Q2Q%-61.81%
3.2 Future
- APDN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 40.85% yearly.
- The Revenue is expected to grow by 45.04% on average over the next years. This is a very strong growth
EPS Next Y92.97%
EPS Next 2Y40.85%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year50.26%
Revenue Next 2Y45.04%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- APDN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year APDN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as APDN's earnings are expected to grow with 40.85% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.85%
EPS Next 3YN/A
5. Dividend
5.1 Amount
- No dividends for APDN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
5.62
+1.35 (+31.62%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)12-15 2025-12-15/amc
Inst OwnersN/A
Inst Owner Change-28.45%
Ins OwnersN/A
Ins Owner Change0%
Market Cap7.25M
Revenue(TTM)3.30M
Net Income(TTM)-67.51M
Analysts43.33
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-195.26%
Min EPS beat(2)-401.63%
Max EPS beat(2)11.11%
EPS beat(4)2
Avg EPS beat(4)-112.93%
Min EPS beat(4)-401.63%
Max EPS beat(4)11.11%
EPS beat(8)5
Avg EPS beat(8)-19.83%
EPS beat(12)8
Avg EPS beat(12)5.22%
EPS beat(16)10
Avg EPS beat(16)-1.91%
Revenue beat(2)0
Avg Revenue beat(2)-47.64%
Min Revenue beat(2)-76.62%
Max Revenue beat(2)-18.66%
Revenue beat(4)1
Avg Revenue beat(4)-23.38%
Min Revenue beat(4)-76.62%
Max Revenue beat(4)13.1%
Revenue beat(8)2
Avg Revenue beat(8)-20.61%
Revenue beat(12)5
Avg Revenue beat(12)-11.63%
Revenue beat(16)9
Avg Revenue beat(16)-3.58%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 2.2 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1 | ||
| P/tB | 1.59 | ||
| EV/EBITDA | N/A |
EPS(TTM)-924.25
EYN/A
EPS(NY)-84.15
Fwd EYN/A
FCF(TTM)-10.28
FCFYN/A
OCF(TTM)-9.75
OCFYN/A
SpS2.56
BVpS5.63
TBVpS3.54
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -679.56% | ||
| ROE | -929.59% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 39.57% | ||
| FCFM | N/A |
ROA(3y)-55.66%
ROA(5y)-76.19%
ROE(3y)-114.94%
ROE(5y)-140.25%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18.42%
GM growth 5Y-18.75%
F-Score4
Asset Turnover0.33
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 205.74% | ||
| Cap/Sales | 20.75% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.76 | ||
| Quick Ratio | 2.6 | ||
| Altman-Z | -54.74 |
F-Score4
WACC10.45%
ROIC/WACCN/A
Cap/Depr(3y)60.08%
Cap/Depr(5y)170.88%
Cap/Sales(3y)7.71%
Cap/Sales(5y)21.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)89.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-109.65%
EPS Next Y92.97%
EPS Next 2Y40.85%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-2.96%
Revenue growth 3Y-27.56%
Revenue growth 5Y-8.63%
Sales Q2Q%-61.81%
Revenue Next Year50.26%
Revenue Next 2Y45.04%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y10.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-86.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-85.04%
OCF growth 3YN/A
OCF growth 5YN/A
APPLIED DNA SCIENCES INC / APDN FAQ
Can you provide the ChartMill fundamental rating for APPLIED DNA SCIENCES INC?
ChartMill assigns a fundamental rating of 3 / 10 to APDN.
What is the valuation status of APPLIED DNA SCIENCES INC (APDN) stock?
ChartMill assigns a valuation rating of 1 / 10 to APPLIED DNA SCIENCES INC (APDN). This can be considered as Overvalued.
Can you provide the profitability details for APPLIED DNA SCIENCES INC?
APPLIED DNA SCIENCES INC (APDN) has a profitability rating of 0 / 10.
What is the expected EPS growth for APPLIED DNA SCIENCES INC (APDN) stock?
The Earnings per Share (EPS) of APPLIED DNA SCIENCES INC (APDN) is expected to grow by 92.97% in the next year.